Ovid Therapeutics (NASDAQ:OVID) Stock Rating Cut to “Sell” at Wall Street Zen

Wall Street Zen lowered shares of Ovid Therapeutics (NASDAQ:OVID – Free Report) from a hold rating to a sell rating in a research report report published on Saturday morning,Wall Street Zen reports.

A number of other equities research analysts have also weighed in on the company. Oppenheimer lifted their target price on Ovid Therapeutics from $7.00 to $9.00 and gave the company an “outperform” rating in a research report on Monday, August 3rd. B. Riley Financial reissued a “buy” rating on shares of Ovid Therapeutics in a research report on Tuesday, July 21st. Weiss Ratings restated a “sell (d-)” rating on shares of Ovid Therapeutics in a research note on Thursday, October 15th. Cantor Fitzgerald began coverage on shares of Ovid Therapeutics in a research note on Friday, October 9th. They issued an “overweight” rating for the company. Finally, UBS Group reiterated a “buy” rating on shares of Ovid Therapeutics in a report on Friday, September 11th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Ovid Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $6.00.

Get Our Latest Analysis on OVID

Ovid Therapeutics Trading Down 0.4%

NASDAQ:OVID traded down $0.01 during mid-day trading on Friday, hitting $2.54. 2,900,318 shares of the stock traded hands, compared to its average volume of 2,556,810. The company has a quick ratio of 12.39, a current ratio of 11.97 and a debt-to-equity ratio of 0.05. Ovid Therapeutics has a 52 week low of $1.18 and a 52 week high of $3.11. The stock has a market capitalization of $479.38 million, a price-to-earnings ratio of -10.58 and a beta of 0.24. The firm’s 50 day moving average is $2.51 and its two-hundred day moving average is $2.40.

Ovid Therapeutics (NASDAQ:OVID – Get Free Report) last issued its earnings results on Tuesday, November 10th. The company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.02). On average, equities research analysts predict that Ovid Therapeutics will post -0.39 earnings per share for the current year.

Hedge Funds Weigh In On Ovid Therapeutics

A number of large investors have recently made changes to their positions in OVID. StoneX Group Inc. purchased a new position in shares of Ovid Therapeutics in the 3rd quarter valued at approximately $51,000. Spark Investment Management LLC acquired a new position in Ovid Therapeutics during the 2nd quarter valued at approximately $86,000. Braidwell LP acquired a new position in Ovid Therapeutics during the 2nd quarter valued at approximately $15,923,000. Two Sigma Securities LLC raised its holdings in shares of Ovid Therapeutics by 182.3% in the second quarter. Two Sigma Securities LLC now owns 71,487 shares of the company’s stock worth $192,000 after buying an additional 46,163 shares during the last quarter. Finally, Wellington Management Group LLP acquired a new stake in shares of Ovid Therapeutics during the second quarter worth $278,000. 72.24% of the stock is owned by institutional investors and hedge funds.

Ovid Therapeutics Company Profile

(Get Free Report)

Ovid Therapeutics Inc. is a biopharmaceutical company focused on developing medicines for epilepsies and other neurological disorders. Its work targets conditions with significant unmet treatment needs, including rare and difficult-to-treat seizure disorders. The company’s lead development program, OV329, is an investigational GABA aminotransferase inhibitor being studied as a potential treatment for seizures, including infantile spasms and focal-onset seizures. Ovid’s pipeline and research programs may change as clinical development progresses.

Read More

Analyst Recommendations for Ovid Therapeutics (NASDAQ:OVID)

Receive News & Ratings for Ovid Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ovid Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.